SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: don jackson who wrote (16)4/13/1997 12:21:00 PM
From: Heat Shock   of 236
 
Greetings.

I appreciate your informed comments very much. You have
the better of me in your contacts and knowledge of investing.

I have a good-sized holding in Stressgen, acquired in early 97
after a lengthy search. My criteria were a) 10-bagger potential,
and b) a company "story" which has intelligent appeal. My plan
is to sit on the shares for 2 - 5 years.

Stressgen played up the "memorandum of understanding" concerning
Genzyme with a press release. I surf to genzyme.com ,
and I see nothing about it in their press releases. Why not?

I can understand Stressgen going down on the press release about
Genzyme when Bre-X crashed and people realized Genzyme is not
a Giga-player in the pharmaceutical world. But on the press
release about pre-clinical gene therapy success, it went down
ANOTHER 40 or 50 cents. This does not make sense to me.

Do you have any sense of how the Stressgen US patent is going?
I assume this is crucial.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News